Clinical Faculty
•
Charles M. Bliss, Jr., M.D.
•
Lizabeth Cline, M.S.R.N., C.S., A.N.P.
•
Francis Farraye, M.D., M.Sc.
•
Albena Halpert, MD
•
Christopher S. Huang, MD
•
Brian Jacobson, M.D., M.P.H.
•
David R. Lichtenstein, M.D.
•
Robert C. Lowe, M.D.
•
Daniel S. Mishkin, M.D.,C.M.
•
T. Carlton Moore, M.D.
•
David P. Nunes, M.D.
•
Jaime Oviedo, M.D.
•
Marcos C. Pedrosa, M.D., M.P.H.
•
Angela C. Reffel, PA-C
•
Lawrence J. Saubermann, M.D.
•
Elihu M. Schimmel, M.D.
•
Paul C. Schroy III, M.D., M.P.H.
•
Satish K. Singh, M.D.
•
Chi-Chuan Tseng, M.D., Ph.D., M.P.H.
•
H. Christian Weber, M.D.
•
M. Michael Wolfe, M.D.
|
|
|
|
Chi-Chuan Tseng, M.D., Ph.D., M.P.H.
One of the major interests of Dr. Tseng's laboratory is to examine the potential role of gut-enriched kruppel-like factor (GKLF) in the
tumorigenesis of the gastrointestinal tract. GKLF is a newly identified zinc finger transciptional factor that is found extensively
in the GI tract. Studies from this laboratory have shown that GKLF expression is down-regulated in both colon cancer and polyps.
He is investigating the function of GKLF in the development of GI tumors. Another major interest of Dr. Tseng's laboratory is to
investigate the cellular and molecular mechanisms regulating glucose-dependent insulinotropic polypeptide (GIP) receptor
desensitization. Several gastrointestinal regulatory peptides, including GIP, have been proposed as incretins due to their ability
to stimulate insulin release from the pancreas. Recent data suggest that elevated serum GIP levels in diabetic patients might
induce chronic desensitization of the GIP receptor, and that this mechanism could contribute to the impaired insulin secretion seen
in these patient. The mechanisms governing these desensitization processes have not been elucidated. Clinically, Dr. Tseng is
interested in all gastrointestinal disorders including acid peptic diseases, malabsorption, diarrhea, inflammatory bowel disease,
and hepatitis.
|
